Advanced Plant Pharmaceuticals, Inc. and Union Bless, Ltd. HongKong to Conduct Research for SARS; Provisional Patent Application Filed for SARS.Business Editors/Health/Medical Writers NEW YORK--(BUSINESS WIRE)--May 21, 2003 Advanced Plant Pharmaceuticals, Inc., (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :APPI APPI American Psychiatric Publishing, Inc. APPI American Psychiatric Publishing Inc. APPI American Psychiatric Press, Inc. APPI Atmospheric Pressure Photoionization APPI Advanced Peer-to-Peer Internetworking APPI Advanced Plant Pharmaceuticals Inc. ) a company that utilizes whole plants through a proprietary (patent pending) manufacturing process to develop nutraceuticals, has announced the signing of an agreement with Union Bless, Ltd. of Hong Kong. Union Bless, Ltd. has agreed to initiate efficacy trials for ABAVCA and the treatment of SARS virus in SARS patients in Hong Kong, China and the Philippines. ABAVCA, which is patented and manufactured by APPI, is an all-natural immunomodulator that has received an IND (investigational new drug) number from the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) and has been approved for Phase I/II clinical studies. In prior clinical studies conducted by APPI, ABAVCA showed promising results in the boosting of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . In case studies of patients using ABAVCA orally, patients experienced the reversal of glandular glandular /glan·du·lar/ (glan´du-ler) 1. pertaining to or of the nature of a gland. 2. glanular. glan·du·lar adj. 1. swelling, restoration of well-being and associated weight gain, improvement in response to skin hypersensitivity hypersensitivity, heightened response in a body tissue to an antigen or foreign substance. The body normally responds to an antigen by producing specific antibodies against it. The antibodies impart immunity for any later exposure to that antigen. tests, increase in blood hemoglobin counts, increase in CD4-counts and improvement in the CD4/CD8 ratio, with many patients returning to a normal ratio. On May 19, 2003, a provisional patent application for ABAVCA and the treatment of SARS was filed with the US Patent and Trademark Office. To date, there have been approximately 7700 cases of persons infected with SARS, with a mortality rate of 8-10%. Patients with a compromised immune system have exhibited a particular vulnerability to SARS.ABAVCA may have the potential to be used as a prophylactic (preventative) and as a treatment for SARS. Although SARS has no geographical boundaries, most of the confirmed cases of SARS have been in China and Hong Kong where Union Bless Ltd. will conduct SARS research. Although APPI makes no claim and has no clinical evidence that ABAVCA is effective on SARS, the clinical trials will be designed to gather the empirical data to prove potential efficacy. For more information on APPI, please visit the Company's Web site at www.advancedplantpharm.com FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described. Risks and uncertainties include, but are not limited to, clinical development, clinical trials, regulatory approvals in targeted market countries, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company and/or other factors, which are outside the control of the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion